Ein Biotech-Startup entwickelt eine personalisierte Krebsimpfung, die auf der Tumormutationslast speziell abgestimmt ist. Ein Patient hat 240 somatische Mutationen in seinen Tumorzellen, und der Impfstoff zielt erfolgreich auf 65 % davon ab. Wie viele Mutationen bleiben nicht anvisiert?

Sat, 02 May 2026 11:14:37 +0000

**How Personalized Cancer Vaccines Address Tumors: What’s Left Untargeted?** With rapid advances in cancer research, personalized immunotherapy is emerging as a transformative frontier—especially for patients with complex tumor profiles. One pioneering company is developing vaccines tailored to the unique genetic makeup of individual tumors, focusing on somatic mutations that drive cancer growth. For a patient with 240 distinct somatic mutations in their tumor cells, early data shows the treatment successfully targets 65% of these mutations. But what remains untargeted—and why does that matter? In a growing dialogue around precision oncology, the concept of “personalized” extends beyond targeting known driver mutations. Each tumor is a complex ecosystem of genetic variation, and immunotherapy strategies must account for how much of a tumor’s DNA remains outside the vaccine’s reach. This raises a precise and clinically relevant question: if 65% of 240 mutations are successfully targeted, how many remain outside the scope of this advanced treatment? ---